UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-A/A
(Amendment
No. 1 to Form 8-A originally filed on August 1, 2007)
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT
TO SECTION 12(b) or (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Cumberland Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Tennessee
|
|
62-1765329 |
(State or other jurisdiction of
|
|
(I.R.S. Employer |
incorporation or organization)
|
|
Identification No.) |
|
|
|
2525 West End Avenue, Suite 950
|
|
37203 |
Nashville, Tennessee
|
|
(Zip Code) |
(Address of principal executive offices) |
|
|
|
|
|
|
|
Name of Each Exchange On Which |
Title of Each Class to be Registered
|
|
Each Class Is To Be Registered |
|
|
|
Common Stock, no par value per share
|
|
The NASDAQ Stock Market LLC |
If this form related to the registration of a class of securities pursuant to Section
12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the
following box: ý
If this form relates to the registration of a class of securities pursuant to Section 12(g) of
the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box:
o
Securities Act registration statement file number to which this form relates: 333-142535
Securities to be registered pursuant to Section 12(g) of the Act: NONE
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrants Securities to be Registered.
A description of the Common Stock, no par value (the Common Stock) of Cumberland Pharmaceuticals
Inc. (the Registrant) is contained in the Registrants Registration Statement on Form S-1 (File
No. 333-142535) filed with the Securities and Exchange Commission, as amended, including any form
of prospectus contained therein filed pursuant to Rule 424(b) under the Securities Act of 1933 (the
Form S-1 Registration Statement), which description is incorporated by reference in this Item 1
to the section of the Form S-1 Registration Statement entitled Description of Capital Stock.
Item 2. Exhibits.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be
filed, because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC
and the securities registered hereby are not being registered pursuant to section 12(g) of the
Exchange Act.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant
has duly caused this registration statement to be signed on its behalf of the undersigned, thereto
duly authorized.
|
|
|
|
|
|
CUMBERLAND PHARMACEUTICALS INC.
Date: August 2, 2007
|
|
|
By: |
/s/ A.J. Kazimi
|
|
|
|
A.J. Kazimi |
|
|
|
Chairman and CEO |
|
|